Search

Corcept Therapeutics Inc

Suletud

SektorTervishoid

114.85 0.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

108.28

Max

116.61

Põhinäitajad

By Trading Economics

Sissetulek

75M

43M

Müük

91M

256M

P/E

Sektori keskmine

248.445

56.432

Aktsiakasum

0.36

Kasumimarginaal

16.782

Töötajad

730

EBITDA

91M

47M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+23.95% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

3. nov 2026

Turustatistika

By TradingEconomics

Turukapital

2.3B

12B

Eelmine avamishind

114.2

Eelmine sulgemishind

114.85

Uudiste sentiment

By Acuity

13%

87%

8 / 339 Pingereas Healthcare

Corcept Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. sept 2026, 20:06 UTC

Corcept Therapeutics Inc is advancing, maintaining significant gains since Friday's close, despite earlier pulling back from a session high.

18. sept 2026, 20:02 UTC

Social Media
News

Shares of Corcept Therapeutics fell sharply despite a positive CHMP opinion on relacorilant for ovarian cancer and a reiterated Buy rating from HC Wainwright.

17. sept 2026, 20:01 UTC

News

Corcept Therapeutics shares are rising, supported by record revenue and net income growth for Q2 2026, along with an increased revenue guidance of up to $1.2 billion.

15. sept 2026, 20:07 UTC

Corcept Therapeutics Inc is trading lower amid a broader market decline, influenced by a significant drop in the NY Empire State Manufacturing Index.

14. sept 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid broader market concerns over rising crude oil prices and inflation ahead of the Federal Reserve's interest rate decision.

11. sept 2026, 20:08 UTC

Corcept Therapeutics Inc shares are lower today, reflecting broader market trends amid volatility and recent inflation data showing a monthly increase of 0.4%.

10. sept 2026, 19:21 UTC

Corcept Therapeutics Inc shares are lower amid broader market declines and rising Treasury yields, with no specific company news identified.

8. sept 2026, 20:07 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early decline. The stock peaked midday but remains below the 20-day moving average.

2. sept 2026, 20:08 UTC

Corcept Therapeutics Inc. shares are lower today, breaking a recent trend of gains. The broader market is impacted by a weak ADP employment report.

1. sept 2026, 20:08 UTC

Corcept Therapeutics Inc shares are lower amid broader market declines driven by rising oil prices and increasing inflation concerns ahead of the Federal Reserve meeting.

28. aug 2026, 20:01 UTC

Corcept Therapeutics Inc shares are lower, continuing a four-day decline amid notable volatility and unusually high market volume. No specific news was identified.

27. aug 2026, 23:42 UTC

Corcept Therapeutics Inc is higher in after-market trading, recovering from earlier lows. Economic data showing a decline in jobless claims may support market sentiment.

26. aug 2026, 19:51 UTC

Corcept Therapeutics Inc shares are lower today, reaching a session low and marking a decline since Tuesday's close, with high trading volume noted.

25. aug 2026, 23:06 UTC

Corcept Therapeutics Inc shares are lower in after-market hours, reflecting a decline since Tuesday's close amid falling crude oil prices and easing geopolitical concerns.

24. aug 2026, 19:36 UTC

News

Corcept Therapeutics shares are lower despite Zacks raising Q3 2026 EPS estimate to $0.34. The company reported Q2 earnings of $0.36 per share.

21. aug 2026, 20:01 UTC

News

Corcept Therapeutics Inc is higher today, supported by strong sector performance and increased trading volume amid a positive growth outlook and upcoming FDA decision on Relacorilant.

20. aug 2026, 23:41 UTC

Corcept Therapeutics Inc. shares are trading roughly flat in after-market hours. The asset remains above its 20-day moving average.

13. aug 2026, 19:46 UTC

Corcept Therapeutics Inc is declining today, with no specific news identified. The stock peaked earlier but has since retraced from that high.

12. aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today amid a positive trend in U.S. stocks, despite geopolitical tensions and rising crude oil prices.

11. aug 2026, 20:06 UTC

Corcept Therapeutics Inc. shares are lower today, having declined steadily after reaching a session high earlier. The stock remains above its 20-day moving average.

10. aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are higher today, recovering from an early drop despite a broader market decline amid labor market concerns.

7. aug 2026, 21:01 UTC

Corcept Therapeutics Inc shares are lower in after-market trading, declining despite being above its 20-day moving average and near the upper end of its one-month range.

5. aug 2026, 19:56 UTC

Corcept Therapeutics Inc's shares are higher today, reflecting a generally positive market environment. The stock remains significantly above its 20-day moving average.

4. aug 2026, 19:16 UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

3. aug 2026, 20:02 UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

31. juuli 2026, 22:26 UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

30. juuli 2026, 23:11 UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

29. juuli 2026, 23:41 UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

28. juuli 2026, 19:46 UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

27. juuli 2026, 23:46 UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

Võrdlus sarnastega

Hinnamuutus

Corcept Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

23.95% tõus

12 kuu keskmine prognoos

Keskmine 141 USD  23.95%

Kõrge 165 USD

Madal 50 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Corcept Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

4

Osta

0

Hoia

1

Müü

Sentiment

By Acuity

8 / 339 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.